Señales en vivo de 2126.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 04:08):

Stats
Volumen de hoy	844 000
Volumen promedio	299 391
Capitalización de mercado	683.95M
EPS	HKD0 ( 2024-04-24 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.840
ATR14	HKD0.0100 (0.58%)

Volumen Correlación

Largo: -0.15 (neutral)

Corto: -0.50 (neutral)

Signal:(46.737) Neutral

JW THERAP-B Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

JW THERAP-B Correlación - Moneda/Commodity

0.61
( weak )

0.50
( weak )

0.00
( neutral )

0.05
( neutral )

JW THERAP-B Finanzas

Annual	2023
Ingresos:	HKD173.86M
Beneficio Bruto:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2023
Ingresos:	HKD173.86M
Beneficio Bruto:	HKD88.22M (50.74 %)
EPS:	HKD-1.870

FY	2022
Ingresos:	HKD145.70M
Beneficio Bruto:	HKD58.76M (40.33 %)
EPS:	HKD-2.06

FY	2021
Ingresos:	HKD30.80M
Beneficio Bruto:	HKD9.05M (29.37 %)
EPS:	HKD-5.32

Financial Reports:

No articles found.

JW THERAP-B

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.